PRE-emptive therapy of acute Graft Versus Host Disease according to specific proteomic patterns after allogeneic haematopoietic stem cell transplantation

Submission date 27/06/2007	Recruitment status No longer recruiting	[X] Prospectively registered
		☐ Protocol
Registration date 19/12/2007	Overall study status Completed	Statistical analysis plan
		☐ Results
Last Edited	Condition category	Individual participant data
02/09/2008	Injury, Occupational Diseases, Poisoning	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Eva M. Mischak-Weissingger

Contact details

Hannover Medical School
Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation
Carl-Neuberg-Str. 1
Hannover
Germany
30625
+49 (0)511 532 9518
mischak-weissinger.eva@mh-hannover.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

497Ganser Weissinger

Study information

Scientific Title

Acronym

PRE-GVHD

Study objectives

Reduction of both severity and/or incidence of acute graft versus host disease (aGvHD) greater than grade II in the pre-emptively treated population as compared to placebo treated group.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The collection/analysis of residual material as used in this study has already been approved by the Ethics Committee of the Hannover Medical School in November 2002 and November 2005 (ref: 3097).

Study design

Prospective, double-blinded randomised placebo-controlled multi-centre study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Graft versus host disease after allogeneic haematopoietic stem cell transplantation

Interventions

Experimental intervention:

Pre-emptive immunosuppressive treatment (daily 2 mg methylprednisone/kg body weight [BW]) immediately at occurrence of an aGvHD grade II-specific proteome pattern.

Control intervention:

Placebo immediately at occurrence of a positive aGvHD grade II-specific proteome pattern.

Duration of intervention per patient:

2 mg/kg/kg BW steroids for five days if no clinical symptoms occur (taper steroids according to taper protocol), or until severity increases (clinical symptoms of aGvHD grade II; increase of symptoms in severity after three days, no change for seven days, intermediate response for 14 days).

In case of clinical aGvHD (greater than grade II) unblinding is necessary: the placebo group will start standard treatment with 2 mg methylprednisone/kg BW, treatment group will be open for second line therapy (e.g. 2 mg methylprednisone/kg BW and Antithymocyte Globulin (ATG) or clinic specific second line therapy).

Experimental and/or control off label or on label in Germany: not applicable. Follow-up per patient: 100 days after HSCT.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methylprednisone

Primary outcome measure

Occurrence of aGvHD (greater than grade II) in placebo versus treatment group, between time of randomisation and 100 days after HSCT.

Secondary outcome measures

- 1. Increased overall survival in treatment group (day +365)
- 2. Reduction of severity of aGvHD (day +120)

Scientific endpoints (measured at end of study: three years):

- 1. Differentiation of aGvHD grade II to IV according to polypeptide markers
- 2. Organ specific aGvHD pattern
- 3. Generation of proteomic patterns for steroid resistant GvHD (will be acquired during the study)
- 4. Normalisation of aGvHD proteome pattern in response to treatment

Overall study start date

01/01/2008

Completion date

31/12/2010

Eligibility

Key inclusion criteria

- 1. All patients greater than 18 years after allogeneic haematopoietic stem cell transplantation (allo-HSCT)
- 2. Informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

580 screening, 260 elegible, 90 randomisation

Key exclusion criteria

- 1. Severe infections at the time of aGvHD-pattern positivity
- 2. No informed consent

Date of first enrolment

01/01/2008

Date of final enrolment

31/12/2010

Locations

Countries of recruitment

Germany

Study participating centre Hannover Medical School

Hannover Germany 30625

Sponsor information

Organisation

Hannover Medical School (Germany)

Sponsor details

c/o Prof. Dr. med. Arnold Ganser Director Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation Carl-Neuberg-Str. 1
Hannover
Germany
30625
+49 (0)511 532 3021
Ganser.Arnold@mh-hannover.de

Sponsor type

Hospital/treatment centre

Website

http://www.mh-hannover.de/index.php?id=2&L=1

ROR

https://ror.org/00f2yqf98

Funder(s)

Funder type

Government

Funder Name

German Federal Ministry of Education and Research (Bundesministerium Für Bildung und Forschung [BMBF]) (Germany) (ref: 497Gasnser_Weissinger)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration